Servier Bio-Innovation
Clinical trials sponsored by Servier Bio-Innovation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New immunotherapy cocktails aim to shrink tough lung tumors Results expected Apr 2027 (estimated)
- New drug combo targets Hard-to-Treat cancers with MTAP deletion Results expected May 2027 (estimated)
- New antibody combo takes on Hard-to-Treat stomach cancers Results expected Aug 2027 (estimated)
-
New hope for rare bone cancer: targeted pill slows tumor growth?
Disease control Recruiting nowThis Phase 3 trial tests ivosidenib, a daily pill that targets a specific genetic mutation (IDH1), in 136 adults with advanced or metastatic conventional chondrosarcoma that cannot be surgically removed. Participants are randomly assigned to receive either ivosidenib or a placebo…
Phase 3 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New study explores ivosidenib dosing for cancer patients with organ issues
Knowledge-focused Recruiting nowThis early-stage study is testing the safety and how the body handles ivosidenib in 30 adults with IDH1-mutated cancers who also have liver or kidney problems. Participants take a daily ivosidenib pill and are monitored closely with blood tests and check-ups. The goal is to learn…
Phase 1 • Sponsor: Servier Bio-Innovation LLC • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC